Search
Denali Therapeutics Inc
DNLIAdd to Watchlist
19.195USD
-0.605-3.06%
Market hours （ET）Quotes delayed by 15 min
3.05BMarket Cap
LossP/E TTM
More Details of Denali Therapeutics Inc Company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Denali Therapeutics Inc Info
Ticker SymbolDNLI
Company nameDenali Therapeutics Inc
IPO dateDec 08, 2017
CEOWatts (Ryan J)
Number of employees422
Security typeOrdinary Share
Fiscal year-endDec 08
Address161 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16508668547
Websitehttps://www.denalitherapeutics.com
Ticker SymbolDNLI
IPO dateDec 08, 2017
CEOWatts (Ryan J)
Company Executives of Denali Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
--
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
--
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
--
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
--
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
352.53K
--
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
72.72K
--
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
27.53K
--
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
26.07K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baillie Gifford & Co.
7.60%
BlackRock Institutional Trust Company, N.A.
6.56%
T. Rowe Price Investment Management, Inc.
4.57%
Biogen Inc
4.51%
Temasek Holdings Pte. Ltd.
4.42%
Other
72.34%
Shareholders
Shareholders
Proportion
Baillie Gifford & Co.
7.60%
BlackRock Institutional Trust Company, N.A.
6.56%
T. Rowe Price Investment Management, Inc.
4.57%
Biogen Inc
4.51%
Temasek Holdings Pte. Ltd.
4.42%
Other
72.34%
Shareholder Types
Shareholders
Proportion
Investment Advisor
52.46%
Investment Advisor/Hedge Fund
21.59%
Hedge Fund
14.03%
Sovereign Wealth Fund
7.64%
Individual Investor
4.62%
Corporation
4.51%
Research Firm
2.29%
Bank and Trust
1.11%
Private Equity
0.63%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
555
158.73M
100.01%
+922.46K
2025Q4
520
148.33M
104.72%
+27.93K
2025Q3
534
148.30M
106.07%
+2.76M
2025Q2
533
144.90M
104.92%
+4.11M
2025Q1
521
140.91M
100.82%
-5.51M
2024Q4
508
135.26M
104.03%
-2.70M
2024Q3
500
139.34M
103.43%
+2.39M
2024Q2
486
129.82M
93.98%
+2.48M
2024Q1
475
127.09M
84.98%
+6.07M
2023Q4
485
116.85M
84.85%
+2.16M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baillie Gifford & Co.
12.31M
7.76%
+719.30K
+6.21%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
10.41M
6.56%
+283.36K
+2.80%
Dec 31, 2025
T. Rowe Price Investment Management, Inc.
7.25M
4.57%
+1.62M
+28.65%
Dec 31, 2025
Biogen Inc
7.16M
4.51%
-5.60M
-43.89%
Oct 30, 2024
Temasek Holdings Pte. Ltd.
7.01M
4.42%
+1.66M
+30.94%
Dec 31, 2025
State Street Investment Management (US)
6.26M
3.95%
+799.11K
+14.62%
Dec 31, 2025
Norges Bank Investment Management (NBIM)
5.12M
3.23%
+1.17M
+29.70%
Dec 31, 2025
Fidelity Management & Research Company LLC
4.79M
3.02%
-223.13K
-4.45%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Neuroscience and Healthcare ETF
4.13%
Global X Guru Index ETF
1.33%
ALPS Medical Breakthroughs ETF
0.98%
Virtus LifeSci Biotech Clinical Trials ETF
0.74%
State Street SPDR S&P Biotech ETF
0.73%
Direxion Daily S&P Biotech Bull 3X Shares
0.45%
Global X Aging Population ETF
0.38%
ProShares Ultra Nasdaq Biotechnology
0.35%
iShares Health Innovation Active ETF
0.35%
Invesco Nasdaq Biotechnology ETF
0.23%
View more
iShares Neuroscience and Healthcare ETF
Proportion4.13%
Global X Guru Index ETF
Proportion1.33%
ALPS Medical Breakthroughs ETF
Proportion0.98%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.74%
State Street SPDR S&P Biotech ETF
Proportion0.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.45%
Global X Aging Population ETF
Proportion0.38%
ProShares Ultra Nasdaq Biotechnology
Proportion0.35%
iShares Health Innovation Active ETF
Proportion0.35%
Invesco Nasdaq Biotechnology ETF
Proportion0.23%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
